Cornerstone Planning Group’s DiaMedica Therapeutics DMAC Stock Holding History

Cornerstone Planning Group’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-80	Closed	-$555	–	563
2026 Q2	$555	Hold	80	–	–	﹤0.01%	1665
2026 Q1	$500	Hold	80	–	–	﹤0.01%	1648
2025 Q4	$675	Buy	80 +74	+1,233%	+$553	﹤0.01%	1443
2025 Q3	$758	Sell	6 -74	-93%	-$401	﹤0.01%	1378
2025 Q2	$359	Hold	80	–	–	﹤0.01%	1388
2025 Q1	$317	Hold	80	–	–	﹤0.01%	1397
2024 Q4	$485	Hold	80	–	–	﹤0.01%	1151
2024 Q3	$346	Buy	+80	New	+$295	﹤0.01%	1165

Other funds holding DMAC

Blue Trust Inc Alpharetta, Georgia $9.5B AUM 13.02% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Cornerstone Planning Group's DMAC Position: Q3 2026 in Review

Cornerstone Planning Group sold out of DiaMedica Therapeutics (DMAC) in Q3 2026, closing a stake of 80 shares — an estimated $555 sold.

Cornerstone Planning Group first reported a position in DMAC in Q3 2024 and held it in 8 quarters. The position peaked at $758 in Q3 2025. 6 funds tracked by Wall St. Rank hold DMAC as of Q3 2026.

Cornerstone Planning Group reported no remaining DiaMedica Therapeutics position as of Q3 2026 after selling out during the quarter.
Cornerstone Planning Group sold 80 DiaMedica Therapeutics shares in Q3 2026, an estimated $555.
Cornerstone Planning Group first reported a position in DiaMedica Therapeutics in Q3 2024 and held it in 8 quarters.
Cornerstone Planning Group's DiaMedica Therapeutics position peaked at $758 in Q3 2025.
6 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2026.

Based on Cornerstone Planning Group's 13F filing for Q3 2026, filed 16 Oct 2026.